SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets open in 5 hrs 55 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
84.45+0.51 (+0.61%)
As of 9:20AM CEST. Market open.
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close83.94
Open84.13
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range84.00 - 84.61
52 Week Range62.50 - 84.61
Volume218,248
Avg. Volume2,264,429
Market Cap106.17B
Beta0.74
PE Ratio (TTM)23.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield3.35 (3.68%)
Ex-Dividend DateN/A
1y Target EstN/A
  • The Wall Street Journal3 hours ago

    FDA Approves Regeneron and Sanofi’s Dupixent for Eczema

    Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy ...

  • American City Business Journals10 hours ago

    FDA approves Sanofi Genzyme drug amid questions over patent, cost

    The FDA has approved a drug to treat eczema made by Cambridge-based Sanofi Genzyme that some analysts believe could eventually surpass $3 billion in annual sales. The agency announced Tuesday that it has approved dupilumab, a treatment for atopic dermatitis that will be sold under the brand name Dupixent. The drug was developed by Sanofi Genzyme, a division of French pharmaceutical giant Sanofi SA (SNY), along with its partner Regeneron Pharmaceuticals (REGN).

  • Regeneron, Sanofi Get Approval For Eczema Drug Priced At $37,000
    Investor's Business Daily11 hours ago

    Regeneron, Sanofi Get Approval For Eczema Drug Priced At $37,000

    Regeneron and Sanofi will price eczema drug Dupixent at $37,000 annually, the companies said Tuesday.